The European Medicines Agency (EMA) approved this Monday, December 20, the marketing in the European Union (EU) of the Nuvaxovid vaccine, by the North American pharmaceutical company Novavax, against Covid-19, for people over 18 years old.
The marketing authorization came after the EMA concluded that data on the vaccine was robust and met EU criteria for efficacy, safety and quality, according to a statement.
The evaluation began on November 17, with Nuvaxovid being the fifth vaccine to receive authorization to be marketed in the EU.
Taken together, the results of two studies show a vaccine efficacy for Nuvaxovid of around 90% for the original strain of SARS-CoV-2 and some worrying variants such as Alpha and Beta.
Data regarding the vaccine's efficacy against other worrying strains, including Omicron, are still limited, stresses the EMA.
Nuvaxovid is a vaccine that contains enough fragments of a protein that is unique to the virus for the humanitarian system to recognize and respond by producing defenses against SARS-CoV-2 infection.
The authorization is valid for the 27 Member States, but the Novavax vaccine should not be used in Portugal since, as was announced in July, it is not included in the planning of vaccination against covid-19.
Four anti-covid-19 vaccines are authorized for sale in the EU: Pfizer BioNtech, Moderna, Astrazeneca and Johnson&Johnson.
Comments